Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol
Year: 2026
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Interventional therapy combined with systemic treatment has demonstrated promising antitumor activity and an overall manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma (HCC). However, prospective evidence supporting the optimal combination strategy remains limited, and the tumor immune microenvironment (TIME) characteristics underlying differential treatment responses have not been systematically elucidated. The present study aims to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with palliative transarterial chemoembolization (TACE), followed by sequential targeted-immunotherapy, in treatment-naïve patients with BCLC stage C HCC, while also exploring the TIME features associated with therapeutic response. METHODS: This study is a prospective, single-arm, phase II clinical trial that will enroll treatment-naïve patients with BCLC C HCC who are unsuitable for surgical resection. Tumor tissue and peripheral blood samples will be collected at baseline prior to treatment initiation. All patients will receive HAIC with a modified FOLFOX regimen combined with palliative TACE. Immediately after the interventional procedure, patients will undergo intra-arterial infusion of bevacizumab (200-300 mg) and intravenous administration of sintilimab (200 mg) every three weeks for a total of six cycles. After two treatment cycles, patients will be stratified according to their treatment response, and five additional tumor tissue and blood samples will be collected from each group. Upon completion of local therapy, patients will continue with maintenance therapy consisting of intravenous bevacizumab (15 mg/kg) and sintilimab (200 mg) every three weeks until disease progression or the development of intolerable toxicity. DISCUSSION: This study will evaluate the efficacy and safety of HAIC combined with palliative TACE followed by sequential targeted-immunotherapy and explore TIME features associated with treatment response. The findings may provide evidence to inform multimodal treatment strategies and personalized therapy for advanced HCC. TRIAL REGISTRATION NUMBER: ChiCTR2500115704.
Source: PLoS ONE
Authors: Yang Fang, Songnan Zhang
Institutions: Yanbian University, Yanbian University Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W7236589523
